RVNC News and Press, Revance Therapeutics Inc. From 12/13/21

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Revance Therapeutics To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - December 13, 2021) - Faruqi & Faruqi, LLP, a leading national securi...

Revance Therapeutics (RVNC +10.7%) shares are on the rise after Aubrey Rankin, President of Innovation & Tech, purchased 30,000 company shares, worth ~$430K. The shares were purchased at $14.33 - $14.50 in a transaction dated Dec 03, 2021. Form 4 A look at Revance Therapeutics' ownership ...

Shares of Revance Therapeutics (RVNC +7.2%) are trading up today following CEO Mark Foley's purchase of 40K shares. Foley acquired the shares yesterday at an average price of $12.90 for a total purchase price of $515,924. He now owns 110,913 shares individually and an additional 769,065 share...

- Two presentations highlighting data on DaxibotulinumtoxinA for Injection, including one oral presentation showcasing new data on clinical immunogenicity from the SAKURA Phase 3 program, and one abstract on injection technique for midface volumization with hyaluronic acid based fille...

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company’s Chief Executive Officer, Mark Foley, and Chief Financial Officer, Tobin Schilke, will participate in a fireside chat at...

New York, New York--(Newsfile Corp. - November 14, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Revance Therapeutics, Inc. ("Revance Therapeutics" or the "Company") (NASDAQ: RVNC). If you suffered losses exceeding $50,000...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Revance Therapeutics To Contact Him Directly To Discuss Their Options NEW YORK - ( NewMediaWire ) - November 12, 2021 - Faruqi & Faruqi, LLP, a leading national securities...

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will participate in the Stifel 2021 Virtual Healthcare Conference, a fully virtual management access conference, taking place No...

Revance Therapeutics, Inc. (RVNC) Q3 2021 Earnings Conference Call November 9, 2021 04:30 PM ET Company Participants Jessica Serra - IR Mark Foley - CEO Dustin Sjuts - President Toby Schilke - CFO Roman Rubio - SVP, Clinical Development Conference Call Participants Ken Cacciatore - Cowen and ...

Image source: The Motley Fool. Revance Therapeutics Inc (NASDAQ: RVNC) Q3 2021 Earnings Call Nov 9, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Revance Therapeutics Inc (RVNC) Q3 2021 Earnings Call Transcript